George M. Deeb, MD, ... David H. Adams, MD , Jeffrey J. Popma, MD
This study evaluated the safety and effectiveness of self-expanding transcatheter aortic valve replacement (TAVR) in patients with surgical valve failure (SVF).
Self-expanding TAVR is superior to medical therapy for patients with severe native aortic valve stenosis at increased surgical risk.
The CoreValve U.S. Expanded Use Study was a prospective, nonrandomized study that enrolled 233 patients with symptomatic SVF who were deemed unsuitable for reoperation. Patients were treated with self-expanding TAVR and evaluated for 30-day and 1-yearoutcomes after the procedure. An independent core laboratory was used to evaluate serial echocardiograms for valve hemodynamics and aortic regurgitation.
Self-expanding TAVR in patients with SVF at increased risk for surgery was associated with a low 1-year mortality and major stroke rate, significantly improved aortic valve hemodynamics, and low rates of moderate and no severe residual aortic regurgitation, with improved quality of life.
- Andrea Colli, MD, David Adams, MD, Alessandro Fiocco, MD, Nicola Pradegan, MD, Lorenzo Longinotti, MD, Matteo Nadali, MD, Dimosthenis Pandis, MD, Gino Gerosa, MD
- Ahmed El-Eshmawi, MD, Dimosthenis Pandis, MD, David H. Adams, MD, Gilbert H. Tang, MD
- Ahmed El-Eshmawi, MD, Javier G. Castillo, MD, David H. Adams, MD
- Joanna Chikwe, MD, Eugene H. Blackstone, MD, David H. Adams, MD